Estuary Biotherapeutics Attains $103M Series A
2026-10-19
Tweet
MENLO PARK, CA, Estuary Biotherapeutics, a biotechnology company developing genetic medicines for patients with serious kidney diseases, announced its launch with $103 million in total committed financing. The $93 million Series A was led by RA Capital Management
Estuary Biotherapeutics, a biotechnology company developing genetic medicines for patients with serious kidney diseases, announced its launch with $103 million in total committed financing.
The $93 million Series A was led by RA Capital Management and included participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a family office connected to an individual living with autosomal dominant polycystic kidney disease (ADPKD). 4BIO Capital and GV, which co-led the company's $10 million seed financing, also participated in the Series A.
The $93 million Series A was led by RA Capital Management and included participation from Deep Track Capital, Biogen New Ventures, UPMC Enterprises, Pivotal bioVenture Partners, the National Kidney Foundation Innovation Fund and a family office connected to an individual living with autosomal dominant polycystic kidney disease (ADPKD). 4BIO Capital and GV, which co-led the company's $10 million seed financing, also participated in the Series A.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors
